Sano Genetics partners with BenevolentAI & C4X Discovery to power precision medicine in Inflammatory Bowel Disease

A new collaboration between Sano Genetics and industry partners aims to accelerate drug and biomarker discovery in ulcerative colitis (UC), a form of Inflammatory Bowel Disease (IBD).

Craig Fox, Chief Scientific Officer, C4X Discovery, added: “Identifying the right drug target for the right patient is a major but challenging goal for drug discovery, particularly for diseases with significant pathophysiological heterogeneity such as ulcerative colitis.

“Our proprietary Taxonomy3 platform will analyse the datasets produced from this research to identify novel drug targets and patient subtypes of UC which may provide a powerful insight into discovering new treatments and enrichment strategies for clinical success.”